4tyd
From Proteopedia
(Difference between revisions)
m (Protected "4tyd" [edit=sysop:move=sysop]) |
|||
| Line 1: | Line 1: | ||
| - | ''' | + | ==Structure-based design of a novel series of azetidine inhibitors of the hepatitis C virus NS3/4A serine protease== |
| + | <StructureSection load='4tyd' size='340' side='right' caption='[[4tyd]], [[Resolution|resolution]] 2.84Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[4tyd]] is a 12 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4TYD OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4TYD FirstGlance]. <br> | ||
| + | </td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=3EO:(4R,6S,7Z,15S,17S)-17-[({7-methoxy-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinolin-4-yl}oxy)methyl]-13-methyl-N-[(1-methylcyclopropyl)sulfonyl]-2,14-dioxo-1,3,13-triazatricyclo[13.2.0.0~4,6~]heptadec-7-ene-4-carboxamide'>3EO</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene><br> | ||
| + | <tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4tyd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4tyd OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4tyd RCSB], [http://www.ebi.ac.uk/pdbsum/4tyd PDBsum]</span></td></tr> | ||
| + | <table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Structural homology between thrombin inhibitors and the early tetrapeptide HCV protease inhibitor led to the bioisosteric replacement of the P2 proline by a 2,4-disubstituted azetidine within the macrocyclic beta-strand mimic. Molecular modeling guided the design of the series. This approach was validated by the excellent activity and selectivity in biochemical and cell based assays of this novel series and confirmed by the co-crystal structure of the inhibitor with the NS3/4A protein (PDB code: 4TYD). | ||
| - | + | Structure-based design of a novel series of azetidine inhibitors of the hepatitis C virus NS3/4A serine protease.,Parsy C, Alexandre FR, Brandt G, Caillet C, Cappelle S, Chaves D, Convard T, Derock M, Gloux D, Griffon Y, Lallos L, Leroy F, Liuzzi M, Loi AG, Moulat L, Musiu C, Rahali H, Roques V, Seifer M, Standring D, Surleraux D Bioorg Med Chem Lett. 2014 Aug 9. pii: S0960-894X(14)00833-6. doi:, 10.1016/j.bmcl.2014.08.002. PMID:25155387<ref>PMID:25155387</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | + | </div> | |
| - | + | == References == | |
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Parsy, C.]] | ||
| + | [[Category: Azetidine inhibitor]] | ||
| + | [[Category: Hcv ns3/4a serine protease]] | ||
| + | [[Category: Hydrolase]] | ||
| + | [[Category: Proteros biostructures gmbh]] | ||
| + | [[Category: Structure-based design]] | ||
Revision as of 09:59, 10 September 2014
Structure-based design of a novel series of azetidine inhibitors of the hepatitis C virus NS3/4A serine protease
| |||||||||||
